Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20321544 | 0.81 | EGFR (0.41) | EGFRJAK2BTKKDM4EMAPT | |
| SCHEMBL21573641 | 0.78 | EGFR (0.45) | EGFRKMT2ALMNA | |
| SCHEMBL29695387 | 0.76 | EGFR (0.52) | EGFR | |
| SCHEMBL2112318 | 0.76 | EGFR (0.52) | EGFR | |
| SCHEMBL21573743 | 0.76 | EGFR (0.42) | EGFRJAK2BTK | |
| SCHEMBL21784552 | 0.75 | ORAI1 (0.42) | KMT2AMEN1ORAI1POLBPDE7A | |
| SCHEMBL21784825 | 0.74 | ORAI1 (0.42) | KMT2AMEN1ORAI1POLBPDE7A | |
| SCHEMBL23772414 | 0.73 | EGFR (0.45) | EGFRJAK2BTK | |
| SCHEMBL17752331 | 0.73 | EGFR (0.45) | EGFRJAK2BTKMAPTNPSR1 | |
| SCHEMBL26266194 | 0.72 | ORAI1 (0.47) | EGFRKMT2AMEN1ORAI1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220109115-A1 | POLYCYCLIC COMPOUND, AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND | IDEMITSU KOSAN CO.,LTD. (JP) | 2022-04-07 | — | — | US | disclosed |
| WO-2020044270-A1 | POLYCYCLIC COMPOUND, AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220109115-A1 | POLYCYCLIC COMPOUND, AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND | ODC1, OTC, PKD1 | EGFR 1976/4885KMT2A 1453/4885MEN1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.